NCT02750358 2025-06-22
Feasibility Study of Adjuvant Enzalutamide for the Treatment of Early Stage AR (+) Triple Negative Breast Cancer
Memorial Sloan Kettering Cancer Center
Phase 2 Active not recruiting
Memorial Sloan Kettering Cancer Center
Servicio Canario de Salud
KU Leuven
Karolinska University Hospital
National Cancer Institute (NCI)